Does Medical Acceleration Improve Outcomes in Ulcerative Colitis Patients Who Are in Clinical Remission but Have Endoscopic Inflammation?

Ji Young Chang, Jae Hee Cheon, Yehyun Park, Soo Jung Park, Tae Il Kim, Won Ho Kim

Research output: Contribution to journalArticle

Abstract

Background: Discrepancies between clinical symptoms and mucosal inflammation have been reported in up to 50% of patients with ulcerative colitis (UC). However, there are no guidelines and only limited information for appropriate treatment manipulation. Aim: We aimed to evaluate long-term outcomes according to treatment strategies and determine predictive factors for disease relapse in UC patients who are in clinical remission (CR) but still have endoscopic inflammation. Methods: A total of 204 patients who were confirmed as achieving CR but still had mucosal inflammation were included. CR was defined as “partial Mayo score ≤ 1” with no changes in medications or use of any corticosteroids during the past 3 months. An active mucosal lesion was defined as “endoscopic Mayo subscore > 0.” Results: The mean patient age was 43.5 years, and 53.9% were male. The mean disease duration was 89.9 months. During a mean follow-up of 34 months, 90 patients (44%) experienced disease relapse. The cumulative relapse-free rate did not differ by treatment strategy (maintenance of current therapy vs. dose elevation or step-up therapy). Multivariate analysis revealed that left-side colitis or pancolitis at diagnosis (OR 2.10; 95% CI 1.04–4.27; P = 0.040) and number of extraintestinal manifestations ≥ 2 (OR 5.62; 95% CI 1.10–28.68; P = 0.038) were independent predictive factors for disease relapse. Conclusions: The current medical acceleration treatment strategy did not have a significant influence on the long-term outcomes of UC patients in CR but with active mucosal inflammation. Disease extent at diagnosis and extraintestinal manifestations were independently predictive of disease relapse.

Original languageEnglish
Pages (from-to)3041-3048
Number of pages8
JournalDigestive diseases and sciences
Volume63
Issue number11
DOIs
Publication statusPublished - 2018 Nov 1

Fingerprint

Ulcerative Colitis
Inflammation
Recurrence
Therapeutics
Colitis
Adrenal Cortex Hormones
Multivariate Analysis
Maintenance
Guidelines

All Science Journal Classification (ASJC) codes

  • Physiology
  • Gastroenterology

Cite this

Chang, Ji Young ; Cheon, Jae Hee ; Park, Yehyun ; Park, Soo Jung ; Kim, Tae Il ; Kim, Won Ho. / Does Medical Acceleration Improve Outcomes in Ulcerative Colitis Patients Who Are in Clinical Remission but Have Endoscopic Inflammation?. In: Digestive diseases and sciences. 2018 ; Vol. 63, No. 11. pp. 3041-3048.
@article{189cdb5536ad4d8aab6c51e6c31d6a12,
title = "Does Medical Acceleration Improve Outcomes in Ulcerative Colitis Patients Who Are in Clinical Remission but Have Endoscopic Inflammation?",
abstract = "Background: Discrepancies between clinical symptoms and mucosal inflammation have been reported in up to 50{\%} of patients with ulcerative colitis (UC). However, there are no guidelines and only limited information for appropriate treatment manipulation. Aim: We aimed to evaluate long-term outcomes according to treatment strategies and determine predictive factors for disease relapse in UC patients who are in clinical remission (CR) but still have endoscopic inflammation. Methods: A total of 204 patients who were confirmed as achieving CR but still had mucosal inflammation were included. CR was defined as “partial Mayo score ≤ 1” with no changes in medications or use of any corticosteroids during the past 3 months. An active mucosal lesion was defined as “endoscopic Mayo subscore > 0.” Results: The mean patient age was 43.5 years, and 53.9{\%} were male. The mean disease duration was 89.9 months. During a mean follow-up of 34 months, 90 patients (44{\%}) experienced disease relapse. The cumulative relapse-free rate did not differ by treatment strategy (maintenance of current therapy vs. dose elevation or step-up therapy). Multivariate analysis revealed that left-side colitis or pancolitis at diagnosis (OR 2.10; 95{\%} CI 1.04–4.27; P = 0.040) and number of extraintestinal manifestations ≥ 2 (OR 5.62; 95{\%} CI 1.10–28.68; P = 0.038) were independent predictive factors for disease relapse. Conclusions: The current medical acceleration treatment strategy did not have a significant influence on the long-term outcomes of UC patients in CR but with active mucosal inflammation. Disease extent at diagnosis and extraintestinal manifestations were independently predictive of disease relapse.",
author = "Chang, {Ji Young} and Cheon, {Jae Hee} and Yehyun Park and Park, {Soo Jung} and Kim, {Tae Il} and Kim, {Won Ho}",
year = "2018",
month = "11",
day = "1",
doi = "10.1007/s10620-018-5193-2",
language = "English",
volume = "63",
pages = "3041--3048",
journal = "American Journal of Digestive Diseases",
issn = "0002-9211",
publisher = "Springer New York",
number = "11",

}

Does Medical Acceleration Improve Outcomes in Ulcerative Colitis Patients Who Are in Clinical Remission but Have Endoscopic Inflammation? / Chang, Ji Young; Cheon, Jae Hee; Park, Yehyun; Park, Soo Jung; Kim, Tae Il; Kim, Won Ho.

In: Digestive diseases and sciences, Vol. 63, No. 11, 01.11.2018, p. 3041-3048.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Does Medical Acceleration Improve Outcomes in Ulcerative Colitis Patients Who Are in Clinical Remission but Have Endoscopic Inflammation?

AU - Chang, Ji Young

AU - Cheon, Jae Hee

AU - Park, Yehyun

AU - Park, Soo Jung

AU - Kim, Tae Il

AU - Kim, Won Ho

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Background: Discrepancies between clinical symptoms and mucosal inflammation have been reported in up to 50% of patients with ulcerative colitis (UC). However, there are no guidelines and only limited information for appropriate treatment manipulation. Aim: We aimed to evaluate long-term outcomes according to treatment strategies and determine predictive factors for disease relapse in UC patients who are in clinical remission (CR) but still have endoscopic inflammation. Methods: A total of 204 patients who were confirmed as achieving CR but still had mucosal inflammation were included. CR was defined as “partial Mayo score ≤ 1” with no changes in medications or use of any corticosteroids during the past 3 months. An active mucosal lesion was defined as “endoscopic Mayo subscore > 0.” Results: The mean patient age was 43.5 years, and 53.9% were male. The mean disease duration was 89.9 months. During a mean follow-up of 34 months, 90 patients (44%) experienced disease relapse. The cumulative relapse-free rate did not differ by treatment strategy (maintenance of current therapy vs. dose elevation or step-up therapy). Multivariate analysis revealed that left-side colitis or pancolitis at diagnosis (OR 2.10; 95% CI 1.04–4.27; P = 0.040) and number of extraintestinal manifestations ≥ 2 (OR 5.62; 95% CI 1.10–28.68; P = 0.038) were independent predictive factors for disease relapse. Conclusions: The current medical acceleration treatment strategy did not have a significant influence on the long-term outcomes of UC patients in CR but with active mucosal inflammation. Disease extent at diagnosis and extraintestinal manifestations were independently predictive of disease relapse.

AB - Background: Discrepancies between clinical symptoms and mucosal inflammation have been reported in up to 50% of patients with ulcerative colitis (UC). However, there are no guidelines and only limited information for appropriate treatment manipulation. Aim: We aimed to evaluate long-term outcomes according to treatment strategies and determine predictive factors for disease relapse in UC patients who are in clinical remission (CR) but still have endoscopic inflammation. Methods: A total of 204 patients who were confirmed as achieving CR but still had mucosal inflammation were included. CR was defined as “partial Mayo score ≤ 1” with no changes in medications or use of any corticosteroids during the past 3 months. An active mucosal lesion was defined as “endoscopic Mayo subscore > 0.” Results: The mean patient age was 43.5 years, and 53.9% were male. The mean disease duration was 89.9 months. During a mean follow-up of 34 months, 90 patients (44%) experienced disease relapse. The cumulative relapse-free rate did not differ by treatment strategy (maintenance of current therapy vs. dose elevation or step-up therapy). Multivariate analysis revealed that left-side colitis or pancolitis at diagnosis (OR 2.10; 95% CI 1.04–4.27; P = 0.040) and number of extraintestinal manifestations ≥ 2 (OR 5.62; 95% CI 1.10–28.68; P = 0.038) were independent predictive factors for disease relapse. Conclusions: The current medical acceleration treatment strategy did not have a significant influence on the long-term outcomes of UC patients in CR but with active mucosal inflammation. Disease extent at diagnosis and extraintestinal manifestations were independently predictive of disease relapse.

UR - http://www.scopus.com/inward/record.url?scp=85049637737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049637737&partnerID=8YFLogxK

U2 - 10.1007/s10620-018-5193-2

DO - 10.1007/s10620-018-5193-2

M3 - Article

C2 - 29987626

AN - SCOPUS:85049637737

VL - 63

SP - 3041

EP - 3048

JO - American Journal of Digestive Diseases

JF - American Journal of Digestive Diseases

SN - 0002-9211

IS - 11

ER -